Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menotropin is a gonadotropin medication consisting of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in a 1:1 ratio, typically extracted from the urine of postmenopausal women. It is a biologic agent used primarily in fertility treatments to induce ovulation and stimulate the development of multiple follicles in the ovaries. In the Cairo University clinical trial (NCT02194335), menotropin (specifically the brand Merional) is being evaluated in a Phase 3 study for its efficacy in stimulated intrauterine insemination (IUI) cycles compared to unstimulated cycles and timed intercourse for women suffering from subfertility associated with endometriosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on menotropin.